194 related articles for article (PubMed ID: 38172843)
41. Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis.
Xu Y; Ma K; Zhang F; Ma M; Hong L; Wang J; Li S; Sun P; Wang J; Wei S
Exp Ther Med; 2023 Aug; 26(2):361. PubMed ID: 37408861
[TBL] [Abstract][Full Text] [Related]
42. The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis.
Zhao N; Xu H; Zhou D; Xu X; Ge W; Cao D
J Gastrointest Oncol; 2022 Aug; 13(4):1772-1781. PubMed ID: 36092324
[TBL] [Abstract][Full Text] [Related]
43. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
[TBL] [Abstract][Full Text] [Related]
44. Aldehyde dehydrogenase serves as a biomarker for worse survival profiles in ovarian cancer patients: an updated meta-analysis.
Xia Y; Wei X; Gong H; Ni Y
BMC Womens Health; 2018 Dec; 18(1):199. PubMed ID: 30522488
[TBL] [Abstract][Full Text] [Related]
45. Prognostic role of C-reactive protein in patients with endometrial cancer: a meta-analysis.
Yu X; Zhang X
Biomark Med; 2024; 18(6):279-289. PubMed ID: 38639733
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of the cancer stem cell marker CD117 predicts poor prognosis in epithelial ovarian cancer patients: evidence from meta-analysis.
Yang B; Yan X; Liu L; Jiang C; Hou S
Onco Targets Ther; 2017; 10():2951-2961. PubMed ID: 28652777
[TBL] [Abstract][Full Text] [Related]
47. Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients With Pancreatic Cancer: A Meta-Analysis.
Xie Q; Wang L; Zheng S
Dose Response; 2020; 18(2):1559325820931290. PubMed ID: 32647499
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis.
Wang Q; Feng X; Liu X; Zhu S
Front Oncol; 2022; 12():868061. PubMed ID: 35463345
[TBL] [Abstract][Full Text] [Related]
49. The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis.
Lu Y; Li L
Technol Cancer Res Treat; 2021; 20():15330338211043784. PubMed ID: 34817271
[No Abstract] [Full Text] [Related]
50. Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.
Zhang WW; Liu KJ; Hu GL; Liang WJ
Tumour Biol; 2015 Nov; 36(11):8831-7. PubMed ID: 26063409
[TBL] [Abstract][Full Text] [Related]
51. Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta-analysis.
Wang Y; Li N; Ren Y; Zhao J
J Obstet Gynaecol Res; 2022 Sep; 48(9):2270-2284. PubMed ID: 35698734
[TBL] [Abstract][Full Text] [Related]
52. Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis.
Wu J; Fu Z; Liu G; Xu P; Xu J; Jia X
Medicine (Baltimore); 2017 Jun; 96(25):e7062. PubMed ID: 28640083
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of baseline C-reactive protein in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Huang Z; Wang K; Huang S; Lu Q
Transl Cancer Res; 2023 Aug; 12(8):2169-2180. PubMed ID: 37701105
[TBL] [Abstract][Full Text] [Related]
54. The prognostic value of the C-reactive protein to albumin ratio in cancer: An updated meta-analysis.
Cui X; Jia Z; Chen D; Xu C; Yang P
Medicine (Baltimore); 2020 Apr; 99(14):e19165. PubMed ID: 32243358
[TBL] [Abstract][Full Text] [Related]
55. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
56. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.
Zhang Z; Xiang Q; Mu G; Xie Q; Chen S; Zhou S; Hu K; Cui YM
Medicine (Baltimore); 2018 Nov; 97(45):e12996. PubMed ID: 30407287
[TBL] [Abstract][Full Text] [Related]
57. Does B7-H4 expression correlate with clinicopathologic characteristics and survival in ovarian cancer?: A systematic review and PRISMA-compliant meta-analysis.
Ye Y; Wang JJ; Li SL; Wang SY; Jing FH
Medicine (Baltimore); 2018 Aug; 97(32):e11821. PubMed ID: 30095655
[TBL] [Abstract][Full Text] [Related]
58. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
[TBL] [Abstract][Full Text] [Related]
59. Expression and clinical significance of survivin in ovarian cancer: A meta-analysis.
He X; Yang K; Wang H; Chen X; Wu H; Yao L; Ma S
PLoS One; 2018; 13(5):e0194463. PubMed ID: 29795564
[TBL] [Abstract][Full Text] [Related]
60. Prognostic and clinicopathologic significance of PLIN2 in cancers: A systematic review with meta-analysis.
Li ML; Luo HY; Quan ZW; Huang LT; Wang JH
Int J Biol Markers; 2023 Mar; 38(1):3-14. PubMed ID: 36604990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
